A new class of inhibitors for the treatment of tuberculosis

用于治疗结核病的新型抑制剂

• 批准号: nhmrc : 1084266
• 负责人: A/Pr James Triccas
• 金额: $ 48.06万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/new-class-inhibitors-treatment-tuberculosis/518993
• 关键词: new; class; inhibitors; treatment; tuberculosis

Tuberculosis (TB) remains a major cause of mortality and morbidity worldwide, with 1.3 million deaths annually. Some strains of the TB bacterium are resistant to all available drugs. We have identified novel chemical structures that display potent and specific activity against pathogenic mycobacteria. In this proposal we will develop optimised derivatives with more potent activity against mycobacteria, assess their stability and toxicity and determine their mode of action.

结核病 (TB) 仍然是全世界死亡和发病的主要原因，每年有 130 万人死亡。某些结核菌菌株对所有现有药物都具有耐药性。我们已经确定了新的化学结构，这些结构对致病性分枝杆菌表现出有效和特异的活性。在本提案中，我们将开发对分枝杆菌具有更强活性的优化衍生物，评估其稳定性和毒性并确定其作用方式。